(News Bulletin 247) – The AstraZeneca laboratory announces that it will present new clinical data at the European Hematology Association (EHA) congress to be held from June 8 to 11, 2023.
The Anglo-Swedish laboratory will present 29 abstracts, 10 of which relate to new drugs, approved or potential, concerning around ten hematological conditions and rare diseases.
In this context, Alexion, an AstraZeneca structure specializing in rare diseases, will notably present the positive results of a phase III trial evaluating danicopan used in addition to standard treatment in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare and serious blood disorder characterized by the destruction of red blood cells.
AstraZeneca will also present (among others) new analyzes of data relating to Calquence (acalabrutinib) in patients with chronic lymphocytic leukemia (CLL), or AZD0486 in patients with relapsed or refractory follicular lymphoma (FL).
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
